Adding complexity

CDOs of CDOs are becoming more popular, particularly among Japanese investors, but dealers warn that the complexity of these products means that they are only suitable for a handful of the most sophisticated investors. Nick Sawyer reports

special-cdos-1-gif

Synthetic arbitrage collateralised debt obligations (CDOs) are still the rage in Asia. In the past few months there’s been a string of new deals, with the most recent entrants – Singapore’s OCBC Bank and Hong Kong-listed China Insurance International Holdings – both launching $1 billion managed synthetic deals in mid-November.

But with the region’s investors becoming more comfortable with synthetic CDOs, a number of banks are looking to the next stage of development – CDOs of CDOs. This is

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Credit risk & modelling – Special report 2021

This Risk special report provides an insight on the challenges facing banks in measuring and mitigating credit risk in the current environment, and the strategies they are deploying to adapt to a more stringent regulatory approach.

The wild world of credit models

The Covid-19 pandemic has induced a kind of schizophrenia in loan-loss models. When the pandemic hit, banks overprovisioned for credit losses on the assumption that the economy would head south. But when government stimulus packages put wads of cash in…

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here